Defender Or Opponent? Amgen Straddles The Biosimilar Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.